Since imatinib is an inhibitor of tyrosine kinase BCR-ABL, c-Kit, PDGFR, and tyrosine kinase subclass 3 family, it is predictable that patients might experience signs and symptoms related to reduced androgen production like gynecomastia. Here, ABL1 is linked to Gynecomastia.